Research ArticleAccepted Article
Cervical Spine Involvement is very rare in Patients with Rheumatoid Arthritis Treated actively with Treat to Target Strategy. Ten-Year Results of the NEORACo Study
Tia Sandström, Vappu Rantalaiho, Timo Yli-Kerttula, Hannu Kautiainen, Timo Malmi, Anna Karjalainen, Tea Uusitalo, Heikki Julkunen, Oili Kaipiainen-Seppänen, Leena Paimela, Kari Puolakka, Toini Uutela, Timo Möttönen, Pekka Hannonen, Marjatta Leirisalo-Repo, Leena Laasonen and Markku Kauppi for the NEO-RACo Study Group
The Journal of Rheumatology November 2019, jrheum.190139; DOI: https://doi.org/10.3899/jrheum.190139
Tia Sandström
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Vappu Rantalaiho
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Timo Yli-Kerttula
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Hannu Kautiainen
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Timo Malmi
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Anna Karjalainen
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Tea Uusitalo
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Heikki Julkunen
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Oili Kaipiainen-Seppänen
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Leena Paimela
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Kari Puolakka
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Toini Uutela
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Timo Möttönen
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Pekka Hannonen
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Marjatta Leirisalo-Repo
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Leena Laasonen
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Markku Kauppi
From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland. This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish. Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Article Information
jrheum.190139
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online November 15, 2019.
Article Versions
- You are currently viewing a Latest version of this article (November 15, 2019 - 04:00).
- latest version (June 1, 2020 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2019 The Journal of Rheumatology
Author Information
- Tia Sandström,
- Vappu Rantalaiho,
- Timo Yli-Kerttula,
- Hannu Kautiainen,
- Timo Malmi,
- Anna Karjalainen,
- Tea Uusitalo,
- Heikki Julkunen,
- Oili Kaipiainen-Seppänen,
- Leena Paimela,
- Kari Puolakka,
- Toini Uutela,
- Timo Möttönen,
- Pekka Hannonen,
- Marjatta Leirisalo-Repo,
- Leena Laasonen and
- Markku Kauppi; for the NEO-RACo Study Group
- From the Department of Rheumatology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Centre for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland; Faculty on Medicine and Health Technology, Tampere University, Tampere, Finland; Department of Rheumatology, Satakunta Central Hospital, Rauma, Finland; Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland; Folkhälsan Research Center, Helsinki, Finland; Department of Medicine, Seinäjoki Central Hospital, Seinäjoki, Finland; Department of Rheumatology, Oulu University Hospital and University of Oulu, Oulu, Finland; Department of Medicine, Hämeenlinna Central Hospital, Hämeenlinna, Finland; Department of Medicine, Kuopio University Hospital, Kuopio, Finland; ORTON Orthopaedic Hospital, Helsinki, Finland; South Karelia Central Hospital, Lappeenranta, Finland; Department of Medicine, Lapland Central Hospital, Rovaniemi, Finland; School of Medicine, University of Turku, Turku, Finland; Department of Rheumatology, Central Hospital of Central Finland, Jyväskylä, Finland; Helsinki Medical Imaging Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland.
This study was financially supported by the Competitive Research Funding of Tampere University Hospital, the Helsinki University Central Hospital Research Funds, Finska Läkaresällskapet, Liv och Hälsa, the Finnish Society for Rheumatology. At baseline an unrestricted grant was provided by Schering-Plough Finland, which was used for the purchase of Infliximab. Schering-Plough Finland also provided support for investigator meetings. The Funders did not have any role in the study design, data collection and analysis, preparation of the manuscript or decision to publish.
Address correspondence to Tia Sandström, Department of Rheumatology, Helsinki University Hospital, PO BOX 372, 00029 HUS, Finland; tia.sandstrom@hus.fi
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Cervical Spine Involvement is very rare in Patients with Rheumatoid Arthritis Treated actively with Treat to Target Strategy. Ten-Year Results of the NEORACo Study
Tia Sandström, Vappu Rantalaiho, Timo Yli-Kerttula, Hannu Kautiainen, Timo Malmi, Anna Karjalainen, Tea Uusitalo, Heikki Julkunen, Oili Kaipiainen-Seppänen, Leena Paimela, Kari Puolakka, Toini Uutela, Timo Möttönen, Pekka Hannonen, Marjatta Leirisalo-Repo, Leena Laasonen, Markku Kauppi
The Journal of Rheumatology Nov 2019, jrheum.190139; DOI: 10.3899/jrheum.190139
Accepted manuscript
Cervical Spine Involvement is very rare in Patients with Rheumatoid Arthritis Treated actively with Treat to Target Strategy. Ten-Year Results of the NEORACo Study
Tia Sandström, Vappu Rantalaiho, Timo Yli-Kerttula, Hannu Kautiainen, Timo Malmi, Anna Karjalainen, Tea Uusitalo, Heikki Julkunen, Oili Kaipiainen-Seppänen, Leena Paimela, Kari Puolakka, Toini Uutela, Timo Möttönen, Pekka Hannonen, Marjatta Leirisalo-Repo, Leena Laasonen, Markku Kauppi
The Journal of Rheumatology Nov 2019, jrheum.190139; DOI: 10.3899/jrheum.190139